Korean J Obstet Gynecol.
2003 May;46(5):1054-1059.
Two Cases of Endometrial Adenocarcinoma Associated with Tamoxifen Use
- Affiliations
-
- 1Department of Obstetrics and Gynecology, College of Medicine, Pusan National University, Busan, Korea.
Abstract
- Tamoxifen citrate is a non-steroidal agent that has demonstrated estrogen agonist and antagonist properties and has found successful application for all stages, as adjuvant therapy, in the treatment of primary breast cancer. The drug was originally introduced for the treatment of high risk postmenopausal women or for postmenopausal patients with advanced disease. Since then, it was reported that long term treatment schedules could provide maximal benefit in preventing recurrences. Recent analyses of clinical trials have demonstrated an increase of disease-free survival in breast cancer among patients with positive estrogen receptor tumor. Tamoxifen is now recommended for chemoprevention of breast cancer in healthy high risk women. An agonist estrogenic effect upon the endometrium, the so called "paradoxical" effect, is suggested when proliferative changes, such as endometrial hyperplasia, adenocarcinoma, polyps. We report a case of endometrial cancer which developed in premenopausal patients with breast cancer under tamoxifen therapy.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Cases with Endometrial Polyp and Endocervical Polyp Associated With Tamoxifen Use
- The Change of Endometrial Thickness in Tamoxifen-treated Postmenopausal Breast Cancer Patients
- Two Cases of Endometrial Carcinoma in Tamoxifen-treated Breast Cancer Patients in Korea
- A giant endometrial polyp with tamoxifen therapy in postmenopausal woman
- Comparative Study on Hysteroscopic and Histologic Examinations of the Endometrium in Postmenopausal Women Taking Tamoxifen
